Total Funding
33
42
Total FundingPost-IPO Equity raised
Growth Score
-5 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
123092
Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.
Baird Radford: Chief Financial OfficerPast Role: Aimmune Therapeutics, SVP finance- Sally Bolmer: VP, Regulatory Affairs and Drug Development
About the Company
Allakos develops antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 immune response plays a key role in pathology, including allergic disease, inflammation, and diseases characterized by excess production of inflammatory cells. Its antibodies target cell types implicated in allergic and inflammatory
responses.
Allakos was founded in 2012 and is headquartered in San Carlos, California.
